Immunovant, INC Form 4 insider transactions

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold 3,242 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Michael Geffner, Chief Medical Officer of Immunovant, sold 3,261 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Jay S. Stout, Immunovant's Chief Technology Officer, sold 7,239 shares of common stock on April 24, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 3,689 shares of common stock on April 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold 1,053 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 4,807 shares of common stock on April 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Director Andrew J. Fromkin reported the acquisition of 11,255 common stock shares and 4,690 stock options, along with the disposal of 99,913 common stock shares.

Director Douglas J. Hughes reported the acquisition of 11,255 restricted stock units and 4,690 stock options in Immunovant, Inc. on April 2, 2024.

Director George V. Migausky reports acquisition of Immunovant stock and stock options on April 2, 2024.

Director Atul Pande reported acquiring shares and stock options in Immunovant, Inc. on April 2, 2024.

Director Frank Torti reports acquiring shares and stock options in Immunovant, Inc. on April 2, 2024.

Jay S. Stout, Chief Technology Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

William L. Macias, Chief Medical Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Michael Geffner, Chief Medical Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Immunovant's CFO, Eva Renee Barnett, reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Peter Salzmann, CEO of Immunovant, Inc., was granted stock options and restricted stock units (RSUs) on April 2, 2024, according to a recent SEC filing.